Format
Sort by
Items per page

Send to

Choose Destination

Selected items

Items: 20

1.

Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial.

Hanania NA, Alpan O, Hamilos DL, Condemi JJ, Reyes-Rivera I, Zhu J, Rosen KE, Eisner MD, Wong DA, Busse W.

Ann Intern Med. 2011 May 3;154(9):573-82. doi: 10.7326/0003-4819-154-9-201105030-00002.

2.

Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children.

Busse WW, Morgan WJ, Gergen PJ, Mitchell HE, Gern JE, Liu AH, Gruchalla RS, Kattan M, Teach SJ, Pongracic JA, Chmiel JF, Steinbach SF, Calatroni A, Togias A, Thompson KM, Szefler SJ, Sorkness CA.

N Engl J Med. 2011 Mar 17;364(11):1005-15. doi: 10.1056/NEJMoa1009705.

3.

Omalizumab: clinical use for the management of asthma.

Thomson NC, Chaudhuri R.

Clin Med Insights Circ Respir Pulm Med. 2012;6:27-40. doi: 10.4137/CCRPM.S7793. Epub 2012 Jun 12.

4.

Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX).

Rubin AS, Souza-Machado A, Andradre-Lima M, Ferreira F, Honda A, Matozo TM; QUALITX Study Investigators..

J Asthma. 2012 Apr;49(3):288-93. doi: 10.3109/02770903.2012.660297. Epub 2012 Feb 23.

PMID:
22356355
5.

Omalizumab: an update on efficacy and safety in moderate-to-severe allergic asthma.

Chipps BE, Figliomeni M, Spector S.

Allergy Asthma Proc. 2012 Sep-Oct;33(5):377-85. doi: 10.2500/aap.2012.33.3599.

PMID:
23026179
6.

Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma.

Gevaert P, Calus L, Van Zele T, Blomme K, De Ruyck N, Bauters W, Hellings P, Brusselle G, De Bacquer D, van Cauwenberge P, Bachert C.

J Allergy Clin Immunol. 2013 Jan;131(1):110-6.e1. doi: 10.1016/j.jaci.2012.07.047. Epub 2012 Sep 27.

PMID:
23021878
7.

Omalizumab therapy in severe asthma: experience from the Spanish registry--some new approaches.

Vennera Mdel C, Pérez De Llano L, Bardagí S, Ausin P, Sanjuas C, González H, Gullón JA, Martínez-Moragón E, Carretero JA, Vera E, Medina JF, Alvarez FJ, Entrenas LM, Padilla A, Irigaray R, Picado C; Spanish Registry..

J Asthma. 2012 May;49(4):416-22. doi: 10.3109/02770903.2012.668255. Epub 2012 Mar 23.

PMID:
22443408
8.

Omalizumab and asthma control in patients with moderate-to-severe allergic asthma: a 6-year pragmatic data review.

Storms W, Bowdish MS, Farrar JR.

Allergy Asthma Proc. 2012 Mar-Apr;33(2):172-7. doi: 10.2500/aap.2012.33.3527.

PMID:
22525394
9.

Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.

Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J, Beeh KM, Ramos S, Canonica GW, Hedgecock S, Fox H, Blogg M, Surrey K.

Allergy. 2005 Mar;60(3):309-16.

10.

Longitudinal changes in asthma control with omalizumab: 2-year interim data from the EXCELS Study.

Eisner MD, Zazzali JL, Miller MK, Bradley MS, Schatz M.

J Asthma. 2012 Aug;49(6):642-8. doi: 10.3109/02770903.2012.690477.

PMID:
22793527
11.

A 26-week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the effect of omalizumab on asthma control in patients with persistent allergic asthma.

Bardelas J, Figliomeni M, Kianifard F, Meng X.

J Asthma. 2012 Mar;49(2):144-52. doi: 10.3109/02770903.2011.648296. Epub 2012 Jan 25.

PMID:
22277052
12.

Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years: a NICE single technology appraisal.

Burch J, Griffin S, McKenna C, Walker S, Paton J, Wright K, Woolacott N.

Pharmacoeconomics. 2012 Nov 1;30(11):991-1004. doi: 10.2165/11597160-000000000-00000. Review.

PMID:
22950547
13.

The oral corticosteroid-sparing effect of omalizumab in children with severe asthma.

Brodlie M, McKean MC, Moss S, Spencer DA.

Arch Dis Child. 2012 Jul;97(7):604-9. doi: 10.1136/archdischild-2011-301570. Epub 2012 Jun 9.

PMID:
22685051
14.

Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE.

Lowe PJ, Renard D.

Br J Clin Pharmacol. 2011 Aug;72(2):306-20. doi: 10.1111/j.1365-2125.2011.03962.x.

15.

Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years.

Walker S, Burch J, McKenna C, Wright K, Griffin S, Woolacott N.

Health Technol Assess. 2011 May;15 Suppl 1:13-21. doi: 10.3310/hta15suppl1/02. Review.

16.

Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.

Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, van As A, Gupta N.

J Allergy Clin Immunol. 2001 Aug;108(2):184-90.

PMID:
11496232
17.

Omalizumab in the treatment of asthma.

Tan R, Corren J.

Expert Rev Respir Med. 2011 Dec;5(6):747-56. doi: 10.1586/ers.11.73. Review.

PMID:
22082161
18.

Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review.

Rodrigo GJ, Neffen H, Castro-Rodriguez JA.

Chest. 2011 Jan;139(1):28-35. doi: 10.1378/chest.10-1194. Epub 2010 Aug 5. Review.

PMID:
20688929
19.

Impact of omalizumab on emergency-department visits, hospitalizations, and corticosteroid use among patients with uncontrolled asthma.

Lafeuille MH, Dean J, Zhang J, Duh MS, Gorsh B, Lefebvre P.

Ann Allergy Asthma Immunol. 2012 Jul;109(1):59-64. doi: 10.1016/j.anai.2012.04.015. Epub 2012 May 12.

PMID:
22727159
20.

Monitoring free serum IgE in severe asthma patients treated with omalizumab.

Korn S, Haasler I, Fliedner F, Becher G, Strohner P, Staatz A, Taube C, Buhl R.

Respir Med. 2012 Nov;106(11):1494-500. doi: 10.1016/j.rmed.2012.07.010. Epub 2012 Aug 11.

Supplemental Content

Support Center